Top Markets
#1 MarsCoin MarsCoin +28.79%
#2 Palladium Network Palladium Network +27.94%
#3 Siren Siren +24.91%
#4 Hive Hive +20.08%
#5 BankrCoin BankrCoin +19.78%
#6 Ankr Network Ankr Network +18.44%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.16%
#8 StonkBroker StonkBroker +14.75%
#9 Pons Pons +11.03%
#10 Status Status +9.74%
Coin of the day
MarsCoin MarsCoin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Orchard Therapeutics plc Orchard Therapeutics plc

Orchard Therapeutics plc

ORTX
Classifica tra le azioni #18160
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing... Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
Prezzo delle azioni
$16.70
Ultima sincronizzazione: 2024-02-02
Capitalizzazione di mercato
$210.34M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
GB
Scambia Orchard Therapeutics plc (ORTX)

Categoria

Healthcare
Ricavi di Orchard Therapeutics plc (ORTX)
Ricavi nel Sep 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Orchard Therapeutics plc, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Orchard Therapeutics plc da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH